The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $ 35 ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

The Biden administration is proposing a new rule to significantly expand the coverage of weight-loss drugs for Americans on ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

News of Biden administration's proposal to require Medicare and Medicaid health insurance to cover weight loss drugs could trigger private employers to do the same.

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.